Life Sciences

  • June 12, 2026

    Insider Trading Defense May Draw On 'Varsity Blues' Playbook

    After enlisting a crew of experienced attorneys, defendants charged in an insider trading case allegedly involving deal information stolen from huge law firms are preparing to use a strategy that could take some cues from the "Varsity Blues" case in the same Boston courthouse.

  • June 12, 2026

    Ex-Honeywell China GC Can't Bring US Bias Suit, Judge Says

    Honeywell International Inc. defeated a lawsuit alleging it unlawfully fired the vice president and general counsel at a Chinese subsidiary because she turned 55, with a North Carolina federal judge saying her employment contract requires the dispute to be handled in China.

  • June 12, 2026

    Taxation With Representation: Gibson Dunn, Davis Polk, S&C

    In this week's Taxation With Representation, SpaceX prices a $75 billion initial public offering at its designated price range, Apollo Global Management leads a capital commitment for a Broadcom initiative to build artificial intelligence infrastructure for companies including Anthropic, and pharma giant GSK acquires cancer therapy specialist Nuvalent.

  • June 11, 2026

    AbbVie Loses Colorado 340B Drug Pricing Law Challenge

    A Colorado federal judge on Wednesday dismissed all of AbbVie Inc.'s claims against the state over its federal 340B drug pricing law, finding that the Colorado law isn't federally preempted and courts across the country have settled the issue.

  • June 11, 2026

    Ex-Pharma Exec Fights SEC 'Shadow Trading' Win At 9th Circ.

    An ex-Medivation Inc. executive urged the Ninth Circuit on Thursday to scrap a jury verdict finding him liable in the U.S. Securities and Exchange Commission's first-ever "shadow trading" case, arguing the company's own policies permitted the trades and affirming the verdict will allow companies to adopt vague trading policies.

  • June 11, 2026

    11th Circ. Seeks Fla., Ga. Justices' Input On Opioid Coverage

    The Eleventh Circuit on Thursday asked justices in Georgia and Florida to weigh in on whether commercial general liability insurers must defend and indemnify Publix Super Markets Inc. and a Georgia-based generic-drug wholesaler against suits claiming they improperly distributed opioids.

  • June 11, 2026

    Stop & Shop Parent Pays $40M On Inflated Drug Price Claims

    Stop & Shop's parent company will pay $40 million to resolve allegations it violated the False Claims Act by failing to report discounted prescription drug prices as "usual and customary" in claims submitted to federal Medicare, Medicaid and TRICARE programs, which resulted in overcharges, the U.S. Department of Justice announced Wednesday.

  • June 11, 2026

    Chinese Biopharma Sues Over National Security Threat Label

    Chinese pharmaceutical company WuXi AppTec sued the U.S. Department of Defense on Thursday, asking a D.C. federal court to set aside the agency's designation of the company as a Chinese military company, which it said was done "without a lawful or factual basis."

  • June 11, 2026

    23andMe To Pay $46.7M To Resolve Data Breach Claims

    The plan administration trust created under the Chapter 11 plan of DNA-testing company 23andMe has struck a deal to pay $46.7 million to data breach claimants, saying the move brings 23andMe one step closer to resolving the fallout of a massive data breach in 2023.

  • June 11, 2026

    Cancer Diagnostics Firm Ignite Inks $150M SPAC Merger

    Precision oncology startup Ignite Proteomics LLC will merge with special purpose acquisition company Copley Acquisition Corp. in a deal valuing Ignite at a pro forma enterprise value of $150 million, the companies announced Thursday.

  • June 11, 2026

    Moderna Says New COVID Vax Doesn't Infringe BioNTech IP

    Moderna has pushed back at BioNTech's patent infringement lawsuit accusing its newer COVID-19 vaccine of exploiting BioNTech's own technology, saying that it never infringed and that the patent was invalid to begin with.

  • June 11, 2026

    7th Circ. Rejects Firms' Bid For More Flea Collar MDL Fees

    The Seventh Circuit on Wednesday affirmed an Illinois federal court's refusal to order a redistribution of attorney fees from a $15 million settlement resolving multidistrict litigation against Bayer and other manufacturers of Seresto flea and tick collars, saying two law firms arguing they were cut out of their fair share failed to timely challenge the fee-allocation process.

  • June 10, 2026

    DexCom Says Diabetes Tech Issue Isn't Investor Fraud

    Medical device maker DexCom Inc. has urged a New York federal judge to toss a proposed investor class action over the reliability of the company's glucose monitoring device, arguing the suit is an attempt to recast good-faith business "as fraud based on routine disagreement between a medical device company and its regulator."

  • June 10, 2026

    Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout

    An investor of rare disease treatment company Catalyst Pharmaceuticals Inc. is attempting to stop a buyout by Italian rival Angelini Pharma SpA, saying Catalyst's deficient proxy statement omits relevant information regarding potential conflicts in the proposed transaction.

  • June 10, 2026

    FDA Rule For Nicotine Pouches Likely Flawed, Judge Says

    The U.S. Food and Drug Administration can't stop companies from selling ZEO Universe synthetic nicotine pouches, a Florida federal court has ruled, saying the agency likely acted illegally when it imposed costly new testing requirements without analyzing their economic effect on small businesses.

  • June 10, 2026

    PTAB Invalidates Inari Embolism Treatment Patent

    The Patent Trial and Appeal Board has invalidated the entirety of an Inari Medical Inc. patent covering the company's thrombectomy products, in a challenge brought by Imperative Care Inc.

  • June 10, 2026

    Greenberg Traurig Hires 2 IP Litigators From Goodwin Procter

    Greenberg Traurig LLP announced Wednesday that it had brought on two veteran litigators from Goodwin Procter LLP to its New York office, bolstering its intellectual property litigation practice as the law evolves to keep pace with ever-changing technological innovations.

  • June 10, 2026

    Alachua Wants DOD's $147M Chapter 11 Claim Slashed To $5M

    Biotech group Alachua Government Services asked a Delaware bankruptcy judge to trim the U.S. Department of Defense's Chapter 11 claim by $142 million, saying the government relied upon inapplicable federal regulations in claims connected to rejected contracts.

  • June 10, 2026

    Abbott Offered Faulty Health Plan Option, Ex-Worker Says

    Abbott Laboratories violated federal benefits law by offering a health plan option with higher premiums and lower deductibles without disclosing that participants would always pay less if they chose a high-deductible plan, according to a proposed class action filed Wednesday in Illinois federal court.

  • June 10, 2026

    J&J Hit With $32M Verdict In LA Baby Powder Cancer Trial

    A Los Angeles jury Tuesday awarded $32 million to the family of a woman who died of mesothelioma and who said she used Johnson's Baby Powder on herself and her children for decades, finding the product was a substantial factor in causing her illness. 

  • June 10, 2026

    AmeriHealth Unit, PBM Look To Escape Pharmacy Fee Suit

    The AmeriHealth Caritas Health Plan and its in-house pharmacy benefits manager asked a federal court to toss a proposed class action over "transmission fees," alleging the law that required disclosure of those fees, Pennsylvania's Human Services Code, doesn't let private parties sue.

  • June 10, 2026

    DC Circ. Asked To Freeze DOJ's Medical Pot Rescheduling

    A trade association for drug-testing companies and a biopharma firm developing marijuana-derived drugs have urged the D.C. Circuit to hit pause on a U.S. Department of Justice rule rescheduling state-sanctioned medical pot while their challenge to the policy change plays out.

  • June 10, 2026

    Amgen Can't Amend Petition To Address Potential Double Tax

    Drugmaker Amgen isn't entitled to amend its petition to protect against possible double taxation after an eight-week trial and briefing in its income-allocation case already have been completed, the U.S. Tax Court said, noting that the trial concluded in January 2025.

  • June 10, 2026

    $25M Patent Verdict Against Ferring Backed By Del. Court

    Swiss drugmaker Ferring Pharmaceuticals Inc. on Wednesday lost its bid to dodge a $25 million verdict in a Delaware federal court patent case over an experimental enema used to treat a particularly deadly form of diarrhea.

  • June 10, 2026

    Goodwin, Covington Lead Parabilis' $670M Upsized IPO

    Venture-backed biotechnology firm Parabilis Medicines hit the public markets Wednesday after raising $670 million in its upsized initial public offering.

Expert Analysis

  • Series

    Competing At Poker Makes Me A Better Lawyer

    Author Photo

    Playing poker in male-dominated rooms taught me to treat skepticism as background noise when my opponents seem to underestimate me, to apply pressure when it matters and to adapt without losing strategic discipline — skills that are all indispensable in restructuring and insolvency matters, says Alexis Gambale at Pashman Stein.

  • Why IPR Slowdown Has Not Led To More Patent Litigation

    Author Photo

    Despite sustained strength in patent application filings and a decline in inter partes review and post-grant review, 2026 has not seen the anticipated surge in patent litigation in district courts and at the U.S. International Trade Commission, potentially due to four reasons, say attorneys at Sterne Kessler.

  • 5 Things Associates Must Ask About Their Firm's Merger Plan

    Author Photo

    The associates who navigate law firm mergers best ask the right questions early, such as inquiring about partners' plans, to assess how the merger could affect their workflow and career path, says Jackie Bokser-LeFebvre at Major Lindsey.

  • Brain Computer Interfaces Boot Up Multipronged Legal Issues

    Author Photo

    As neurotechnology companies begin to conduct human clinical trials for brain computer interfaces, attorneys should prepare for legal ramifications across a broad range of practice areas, including intellectual property, privacy and product liability, say attorneys at ArentFox Schiff.

  • Turning To The Courts When PBM Reform Falls Short

    Author Photo

    The effectiveness of state laws intended to regulate pharmacy benefit managers remains uncertain, but litigation — utilizing tried-and-true theories like breach of contract and fair dealing — offers another mechanism through which stakeholders may seek relief from PBMs, say attorneys at Reed Smith.

  • 2 'Rocket Dockets' And The Rules That Propel Them

    Author Photo

    The fastest civil trial courts in the country are currently in the Eastern District of Virginia and the Southern District of Florida, and their chief judges provide insights into the court rules that keep them ahead, says Robert Tata at Hunton.

  • Calif. Ruling Lowers Bar For Health Data Breach Claims

    Author Photo

    The California Supreme Court's ruling in J.M. v. Illuminate Education offers protection for non-healthcare companies that maintain health-related data but also adopts a new and more plaintiff-favorable standard for breach of confidentiality that companies maintaining any health-related data should address, say attorneys at Cooley.

  • Teva Ruling Offers Patentees New Support For Genus Claims

    Author Photo

    The Federal Circuit's recent decision in Teva v. Eli Lilly, finding that the Teva patents at issue are not invalid, offers an interesting counterexample against the recent trend of courts invalidating patents claiming a broad, functionally defined class of compounds, say attorneys at Cooley.

  • Your Next Litigation Hold Should Cover AI Chat Logs

    Author Photo

    The Delaware Chancery Court’s recent decision in Fortis Advisors v. Krafton to treat a CEO’s artificial intelligence chats as substantive evidence is being read as a discovery warning to litigators, but there is a second duty-to-preserve lesson that is especially pertinent to in-house counsel, say attorneys at Faegre Drinker.

  • Opinion

    High Court's Abortion Pill Stay Reinforces Appellate Principles

    Author Photo

    The U.S. Supreme Court's recent order in Danco Laboratories v. Louisiana, staying a Fifth Circuit ruling that reinstated an in-person requirement for dispensing the abortion medicine mifepristone, should be seen not as a definitive ruling on reproductive rights, but as an affirmation of a more disciplined jurisdictional reality, says Daniel Nardo at Nardo & Associates.

  • Cannabis Policy Shift May Reshape Banking, Insolvency Risks

    Author Photo

    The Trump administration's cannabis rescheduling initiative aims to correct classification that had rendered federal banking, tax administration and insolvency law incoherent, and will begin to restore some alignment between federal law and the economic reality of the marijuana industry, says Richard Ormond at Buchalter.

  • Opinion

    International Patent Licensing System Must Be Maintained

    Author Photo

    As foreign approaches to patent enforcement threaten to distort the licensing markets that underpin modern technology, courts and policymakers must take action to ensure that the standard essential patent framework is preserved, says Brian O'Shaughnessy at Dinsmore.

  • Series

    Studying Foreign Languages Makes Me A Better Lawyer

    Author Photo

    Studying Italian and Japanese has shown me that learning a new language can benefit a legal career in several ways, including by demonstrating the importance of approaching problems from a fresh perspective and the value of practicing patience with colleagues and clients, says Anna King at Genworth Financial.

  • 10 US Patent Pressure Points For EU Life Sciences Cos.

    Author Photo

    U.S.-specific patent issues can be challenging for European life sciences companies because they require decisions at the intersection of legal, scientific, regulatory and commercial functions, necessitating proactive, cross-functional steps from EU patent counsel, says Paul Calvo at Sterne Kessler.

  • Sizing Up The Rescheduling Hurdles Medical Pot Cos. Face

    Author Photo

    The Justice Department’s recent lowering of certain medical marijuana products to Schedule III means operators — particularly those simultaneously offering federally illegal adult-use cannabis — must implement greater structural discipline to navigate an increasingly fragmented legal landscape if they hope to benefit from new tax deductions and access to capital, say attorneys at Akerman.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.